Retatrutide
InvestigationalGLP-1 / GIP / glucagon triple agonist
Also known as: LY3437943, triple-G
Investigational. In clinical trials, not approved by the FDA. Any product sold now is unapproved and unverified.
A real evidence base, with gaps
- Regulatory standing. In clinical trials, not yet approved
- Limited human data. Some human data exists, not conclusive
- Registered human trials. 33 registered studies on ClinicalTrials.gov, most advanced Phase 3
- 1 cited source. Includes primary / regulatory sources
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven so far: Phase 2 human data showing up to about 24% weight loss at 48 weeks, the most of any GLP-1-based drug in trials to date. NOT yet proven: long-term safety. Phase 3 is ongoing. Anything for sale now is from an unregulated source.
What it is
Activates three receptors (GLP-1, GIP and glucagon), which may increase energy expenditure on top of appetite reduction.
What the research says
A Phase 2 trial reported around 24.2% mean weight loss at 48 weeks in obesity. Larger Phase 3 trials are ongoing.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Retatrutide is the intervention being tested.
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
FDA recalls & enforcement
Retatrutide has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- Not approved: long-term safety is still being studied, and it caused the most side effects among GLP-1-based drugs in a meta-analysis.
- Anything sold as retatrutide today is from an unregulated source with no verified supply chain.
Doses reported in studies & protocols
Trial doses are still being established. There is no approved dose. This is not a recommendation.
Purity reality
No legitimate consumer supply exists. Gray-market samples cannot be assumed to be what the label says.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.